Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

NCT05467722 PHASE1 COMPLETED

This is an open-label, single-dose, single-period, parallel group designed study to determine the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.

Details

Lead sponsor	Concert Pharmaceuticals
Phase	PHASE1
Status	COMPLETED
Enrolment	21
Start date	Wed Jun 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hepatic Impairment

Interventions

• CTP-543

Countries

United States